Phase I topotecan preparative regimen for high-risk neuroblastoma, high-grade glioma, and refractory/recurrent pediatric solid tumors.
We evaluated the toxicity and maximum tolerated dose of topotecan in a novel myeloablative regimen as treatment for high-risk pediatric tumors. Patients received an assigned topotecan dosage in combination with fixed doses of carboplatin and thiotepa, followed by autologous hematopoietic stem cells infusion. Topotecan dose was escalated in cohorts of four patients until the maximum tolerated dose of topotecan was defined or until accrual of 30 patients. Pharmacokinetics of topotecan were examined, and event-free survival was estimated. We describe preliminary results following treatment of 25 pediatric patients with high-risk solid tumors.
Park
J R
JR
Department of Pediatrics, Children's Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA. jpark2@chmc.org
Slattery
J
J
Gooley
T
T
Hawkins
D
D
Lindsley
K
K
Villablanca
J G
JG
Matthay
K K
KK
Sanders
J E
JE
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005910:Glioma / Q000188:drug therapy* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000628:therapy; D009447:Neuroblastoma / Q000188:drug therapy* / Q000628:therapy; D019772:Topotecan / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D019772:Topotecan